CoChat

Persistence of Prolonged C-peptide Production in Type 1 Diabetes as Measured With an Ultrasensitive C-peptide Assay

Open access

The DOI matches its Crossref record; the references it cites are not checked yet; 1 of the 34 sources its claims cite were checked for support.

Abstract

OBJECTIVE: To examine persistence of C-peptide production by ultrasensitive assay years after onset of type 1 diabetes and factors associated with preserving β-cell function. RESEARCH DESIGN AND METHODS: Serum C-peptide levels, a marker of insulin production and surviving β-cells, were measured in human subjects (n = 182) by ultrasensitive assay, as was β-cell functioning. Twenty-two times more sensitive than standard assays, this assay's lower detection limit is 1.5 pmol/L. Disease duration, age at onset, age, sex, and autoantibody titers were analyzed by regression analysis to determine their relationship to C-peptide production. Another group of four patients was serially studied for up to 20 weeks to examine C-peptide levels and functioning. RESULTS: The ultrasensitive assay detected C-peptide in 10% of individuals 31-40 years after disease onset and with percentages higher at shorter duration. Levels as low as 2.8 ± 1.1 pmol/L responded to hyperglycemia with increased C-peptide production, indicating residual β-cell functioning. Several other analyses showed that β-cells, whose C-peptide production was formerly undetectable, were capable of functioning. Multivariate analysis found disease duration (β = -2.721; P = 0.005) and level of zinc transporter 8 autoantibodies (β = 0.127; P = 0.015) significantly associated with C-peptide production. Unexpectedly, onset at >40 years of age was associated with low C-peptide production, despite short disease duration. CONCLUSIONS: The ultrasensitive assay revealed that C-peptide production persists for decades after disease onset and remains functionally responsive. These findings suggest that patients with advanced disease, whose β-cell function was thought to have long ceased, may benefit from interventions to preserve β-cell function or to prevent complications.

Overview

CoChat Summary

## TL;DR

Using an ultrasensitive C-peptide assay in 182 people with type 1 diabetes, the paper found detectable C-peptide in some patients decades after diagnosis, including 10% at 31–40 years after onset. The detectable C-peptide was still functionally responsive to hyperglycemia, suggesting residual β-cell activity long after clinical onset.

## Key findings

  • In 182 subjects, the ultrasensitive assay had a lower detection limit of 1.5 pmol/L, versus 15 pmol/L for the regular Mercodia assay and 33.1 pmol/L for the Cobas assay used in serial samples.
  • Across disease-duration groups, detectable C-peptide declined over decades; rates above the detection limit were 78.9%, 59.5%, 39.5%, 39.1%, 10%, and 0% from the shortest to longest duration groups, and 10% of individuals had detectable C-peptide 31–40 years after onset.
  • In serially studied patients, the ultrasensitive assay detected C-peptide in 34 of 54 samples (63%) when the standard assay was below detection in all 54/54 samples.
  • Functional responsiveness persisted: samples with hyperglycemia had higher C-peptide than normoglycemia, including levels as low as 2.8 ± 1.1 pmol/L, and multivariate analysis found disease duration (β = −2.721; P = 0.005) and ZnT8 autoantibody level (β = 0.127; P = 0.015) were significantly associated with C-peptide production.

## Methods

  • Observational study of 182 people with type 1 diabetes recruited over 10 years at Massachusetts General Hospital; most analyses used one fasting serum sample per participant, with 4 additional long-term patients followed serially for up to 20 weeks.
  • Serum C-peptide was measured with a Mercodia ultrasensitive ELISA (detection limit 1.5 pmol/L) and compared with standard assays; autoantibodies GADA, IA-2A, and ZnT8A were measured, and glycemia was used to assess functional response.
  • Statistical analysis used unpaired t tests with Welch correction, Pearson correlation, and univariate/multivariate regression; regression was limited to 125 patients with complete variables.

## Limitations

  • The paper states that the age-at-onset analysis was incomplete/unfinished in the text provided, and the authors explicitly say the possible effect of onset after age 40 “needs to be confirmed in further studies, and in additional subject sets.”
  • The study notes that regression analyses were limited to 125 of 182 patients because only those had all variables collected; this reduces the sample for multivariable inference.
  • Evident from the design: it is a single-center observational study with a relatively small serial subgroup (4 patients), so causality cannot be inferred and the serial findings are based on few individuals.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.2337/dc11-1236

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Figures

Figure 1 Sensitivity of standard (Cobas/Roche) versus ultrasensitive (Mercodia) C-peptide assays in a cohort of individuals with type 1 diabetes for whom weekly samples were taken for up to 20 weeks (n = 4 subjects, n = 54 blood samples). Each blood sample was tested by both assays. The shaded areas represent the areas below the detection limits of the assay. A: Standard assay failed to detect C-peptide in any of the selected serum sample. The shaded area across the lower portion of the panel displays the limit of detection of the Cobas assay (33.1 pmol/L), a limit defined as a maintained CV of 1.9%. B: Ultrasensitive assay detected C-peptide in the majority of the same samples. The dashed horizontal line across the entire lower portion of the panel displays the limit of detection (1.5 pmol/L). C and D: Samples taken from four patients studied for functional responses to glycemic level. Samples depicting hyperglycemia (glucose >150 mg/dL) and normoglycemia (glucose ≤150 mg/dL) revealed that C-peptide level was elevated with mild hyperglycemia, as opposed to normoglycemia, by ultrasensitive assay (D). The standard assay is not sensitive enough to reveal this functional response (C). (A high-quality color representation of this figure is available in the online issue.)
Figure 1 Sensitivity of standard (Cobas/Roche) versus ultrasensitive (Mercodia) C-peptide assays in a cohort of individuals with type 1 diabetes for whom weekly samples were taken for up to 20 weeks (n = 4 subjects, n = 54 blood samples). Each blood sample was tested by both assays. The shaded areas represent the areas below the detection limits of the assay. A: Standard assay failed to detect C-peptide in any of the selected serum sample. The shaded area across the lower portion of the panel displays the limit of detection of the Cobas assay (33.1 pmol/L), a limit defined as a maintained CV of 1.9%. B: Ultrasensitive assay detected C-peptide in the majority of the same samples. The dashed horizontal line across the entire lower portion of the panel displays the limit of detection (1.5 pmol/L). C and D: Samples taken from four patients studied for functional responses to glycemic level. Samples depicting hyperglycemia (glucose >150 mg/dL) and normoglycemia (glucose ≤150 mg/dL) revealed that C-peptide level was elevated with mild hyperglycemia, as opposed to normoglycemia, by ultrasensitive assay (D). The standard assay is not sensitive enough to reveal this functional response (C). (A high-quality color representation of this figure is available in the online issue.)CC BY-NC-ND · PubMed Central
Figure 2 The relationships between C-peptide production and disease duration in subjects with type 1 diabetes (n = 182) by ultrasensitive assay. A: Stratified by six intervals of disease duration, in years, subjects with shorter disease duration tended to produce higher levels of C-peptide by the ultrasensitive assay for values up to 230 pmol/L or with the Mercodia regular assay for values >230 pmol/L, which persisted decades after disease onset. The shaded area across the lower portion of the panel displays the limit of detection of the ultrasensitive assay 1.5 pmol/L. B: Percentage of patients with detectable C-peptide above detection limits. (A high-quality color representation of this figure is available in the online issue.)
Figure 2 The relationships between C-peptide production and disease duration in subjects with type 1 diabetes (n = 182) by ultrasensitive assay. A: Stratified by six intervals of disease duration, in years, subjects with shorter disease duration tended to produce higher levels of C-peptide by the ultrasensitive assay for values up to 230 pmol/L or with the Mercodia regular assay for values >230 pmol/L, which persisted decades after disease onset. The shaded area across the lower portion of the panel displays the limit of detection of the ultrasensitive assay 1.5 pmol/L. B: Percentage of patients with detectable C-peptide above detection limits. (A high-quality color representation of this figure is available in the online issue.)CC BY-NC-ND · PubMed Central
Figure 3 Investigating functionality of insulin-secreting β-cells based on blood glucose (A–D) or age at onset and lifetime duration of the C-peptide response (E and F) defines the time line of persistent C-peptide section (G). Hyperglycemic (n = 52) or normoglycemic (n = 52) samples were examined in the same subjects (n = 52), who gave samples on consecutive weeks and stratified into four ranges of C-peptide levels: 0–5 pmol/L (nonresponsive), 0–5 pmol/L (responsive), 5–100 pmol/L, and >100 pmol/L (A–D). Significantly higher C-peptide levels were produced in hyperglycemic samples, except around the lower levels of assay detection (range 0–5 pmol/L), where β-cells from some samples did not respond to hyperglycemia. Subjects divided into six groups based on age at onset produced varying levels of C-peptide, with the highest levels produced at ages 31–40 years and a sudden drop in the group >40 years old and studied for remaining C-peptide secretion (E and F). C-peptide production during and after type 1 diabetes diagnosis. Reduction of C-peptide levels starts sometime during the prediabetes stage and keeps going down with the progress of the disease. With the new ultrasensitive C-peptide assays, remaining β-cell function extends for years after loss of pancreas function and in some cases extends to 40 years after diagnosis (G).
Figure 3 Investigating functionality of insulin-secreting β-cells based on blood glucose (A–D) or age at onset and lifetime duration of the C-peptide response (E and F) defines the time line of persistent C-peptide section (G). Hyperglycemic (n = 52) or normoglycemic (n = 52) samples were examined in the same subjects (n = 52), who gave samples on consecutive weeks and stratified into four ranges of C-peptide levels: 0–5 pmol/L (nonresponsive), 0–5 pmol/L (responsive), 5–100 pmol/L, and >100 pmol/L (A–D). Significantly higher C-peptide levels were produced in hyperglycemic samples, except around the lower levels of assay detection (range 0–5 pmol/L), where β-cells from some samples did not respond to hyperglycemia. Subjects divided into six groups based on age at onset produced varying levels of C-peptide, with the highest levels produced at ages 31–40 years and a sudden drop in the group >40 years old and studied for remaining C-peptide secretion (E and F). C-peptide production during and after type 1 diabetes diagnosis. Reduction of C-peptide levels starts sometime during the prediabetes stage and keeps going down with the progress of the disease. With the new ultrasensitive C-peptide assays, remaining β-cell function extends for years after loss of pancreas function and in some cases extends to 40 years after diagnosis (G).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

1 Valid · 1 Not valid · 18 Not checked · 29 Own results and interpretations

18 more claims

Create a free account to see all 49 claims and to verify the 33 references still open.

See all claims — free account
  • Probably not a substantial claim. 15
  • It may state two separate claims as one. 15
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

The citation lists are queued

They are fetched later and appear here then.

References 23 · Cited by 192

Metadata

Authors
Wang, L., Lovejoy, N. F., & Faustman, D. L.
Affiliations
Harvard University (US)
Corresponding author
Wang, Limei
Venue
Diabetes Care
Published
2012-02-10
Volume
35
Issue
3
Pages
465-470
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2100190220
Cited by
192
References
23
Citations by year
2026: 5 · 2025: 9 · 2024: 10 · 2023: 6 · 2022: 7 · 2021: 15 · 2020: 12 · 2019: 17 · 2018: 23 · 2017: 15 · 2016: 13 · 2015: 17 · 2014: 19 · 2013: 16 · 2012: 7
FWCI
11.37
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
type 1 diabetes, C-peptide, residual beta-cell function, disease duration, zinc transporter 8 autoantibodies, age of onset, beta-cell preservation
MeSH terms
Adolescent, Adult, Aged, Aged, 80 and over, Biological Assay, C-Peptide, Child, Diabetes Mellitus, Type 1, Female, Humans, Male, Middle Aged, Reproducibility of Results, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Persistence of Prolonged C-peptide Production in Type 1 Diabetes as Measured With an Ultrasensitive C-peptide Assay. https://app.cochat.ai/papers/10.2337/dc11-1236
The paper
Wang, L., Lovejoy, N. F., & Faustman, D. L. (2012). Persistence of Prolonged C-peptide Production in Type 1 Diabetes as Measured With an Ultrasensitive C-peptide Assay. Diabetes Care. https://doi.org/10.2337/dc11-1236

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.